Booster Dose Of Pertussis Vaccine Research Articles

Comparing the pertussis antibody levels of healthy children immunized with four doses of DTap-IPV/Hib (Pentaxim) combination vaccine and DTaP vaccine in Quzhou, China.

Despite the high coverage of pertussis vaccines in high-income countries, pertussis resurgence has been reported in recent years, and has stimulated interest in the effects of vaccines and vaccination strategies. Immunoglobulin G (IgG) antibodies against pertussis toxoid (PT), filamentous hemagglutinin (FHA), and pertactin (PRN) after immunization with four doses of co-purified or component vaccines were determined by enzyme-linked immunosorbent assay (ELISA). Serological data of PT-IgG geometric mean concentrations (GMCs) over time since vaccination were used to fit the mathematical models. A total of 953 children were included in this study; 590 participants received four doses of the component acellular vaccine and 363 participants received four doses of the co-purified acellular vaccine. The GMCs and the seropositivity rate of pertussis IgG were significantly influenced by the production methods, and the immunogenicity of the component acellular vaccine was superior to that of the co-purified acellular vaccine. The fitted mathematical models for the component acellular vaccine and the co-purified acellular vaccine were Y=91.20e-0.039x and Y=37.71x-0.493, respectively. The initial GMCs of the component acellular vaccine was higher than that of the co-purified acellular vaccine, but both were similar at 72 months after immunization. Pertussis IgG levels waned over time after four doses of acellular pertussis vaccine, regardless of whether component or co-purified vaccine was used. The development and promotion of component acellular pertussis vaccines should be accelerated in China, and booster doses of pertussis vaccine in adolescents, adults, and pregnant women should be employed.

472Long-term effectiveness of 3-dose primary course and 4-year booster dose of pertussis vaccine in Australia

Abstract Background Australia’s National Immunisation Program recommended a 3-dose primary Diphtheria-Tetanus-Pertussis (DTP) vaccination course at 2, 4 and 6 months and a booster dose at 4 years during 2003-2015. We examined vaccine effectiveness by time since doses 3 and 4, as studies to date have shown conflicting results. Methods Perinatal, immunisation, pertussis notification and death data were linked for 1,086,319 infants born in two Australian states in 2003-2012. Administration of DTP doses 3 and 4 from 5.5-7 months and 47-53 months respectively, was considered age-appropriate. Adjusted Cox proportional hazards models with time-varying vaccination status were used to estimate vaccine effectiveness (VE = 1–hazard ratio) against notified pertussis post age-appropriate doses 3 and 4 compared to unvaccinated children, with additional benefit of dose 4 compared to receipt of primary course alone. Results Dose 3 VE declined from 79% (CI 75%-83%) from 0-6 months to 64% (CI 60%-67%) at 6-36 months and 45% (CI 31%-56%) at 36-42 months post-vaccination. Compared to unvaccinated children, VE after dose 4 declined from 83% (CI 80%-86%) at 0-12 months to 67% (CI 60%-72%) and 55% (CI 46%-63%) in the following two 12-month periods post-vaccination. When compared to dose 3, the relative VE for dose 4 was 58% (CI 51%-64%) in 0-18 months post-vaccination. Conclusion and Key messages Our study adds to previous Australian evidence for substantial waning of vaccine induced immunity against pertussis over a 3-year period following dose 3. VE was significantly higher in the 18 months following dose 4 compared to receipt of primary course alone.

Cross-sectional seroprevalence study of antibody to Bordetella pertussis toxin in western Saudi Arabia: is there a need for a vaccine booster dose for adolescents and young adults?

ObjectivesThe present study was conducted to estimate the seroprevalence of antibody to pertussis toxin among adult populations in western Saudi Arabia.DesignA cross-sectional study.SettingKing Abdulaziz Medical City, Jeddah, western Saudi Arabia....

Causes and consequences of delayed vaccination against pertussis infection in the Russian Federation

Introduction. One of the reasons for the increase of pertussis in the Russian Federation on the background of the widespread coverage of prophylactic vaccinations of more than 95% is a large number of unreasonable medical recusals and parental refusals and, as a result, untimely prophylactic vaccinations against pertussis infection.Materials and methods. We analyzed 5101 emergency notifications for pertussis in children under 17 years of age in Moscow in 2012-2017 and 300 child development histories for children under 14 years of age in two clinics in Moscow. A сase-сontrol study was conducted to assess the relationship between pertussis and the presence of deviations in the immunization schedule.Results. It was found that the level of timely immunization against pertussis did not exceed 5%. Medical (20%) and parental refusals (45%) prevail among the reasons for delayed vaccination. In the structure of medical exemption, the main causes are perinatal encephalopathy, congenital heart defects, intestinal dysbiosis, allergic diseases, anemia and some chronic diseases.Discussion. The main principle for the formation of a full protective immunity from pertussis infection is the mandatory administration of a full primary course of vaccination against pertussis, with the completion of three vaccinations at the age of 10-12 months and mandatory control over the timely receipt of a booster dose no later than the child reaches two years of age. In addition, it is necessary to introduce additional booster doses of pertussis vaccine at the age of 6-7 years, 12-14 years, vaccination of adults every 10 years, as well as consider the introduction of vaccination of expectant mothers in each pregnancy at 27-36 weeks, vaccination for medical personnel and employees who provide child care services.

Seroepidemiology of pertussis in Hangzhou, China, during 2009–2017

ABSTRACTObjective: To delineate seroepidemiology of pertussis in Hangzhou, to evaluate the protection levels of pertussis among healthy populations, for improving prevention strategy of pertussis.Methods: During 2009–2017, a multistage stratified random sampling method was employed to select participants included via physical examination for subjects in several Community Health Centers in Hangzhou. Enzyme-Linked Immunosorbent Assay (ELISA) was used to detect Immunoglobulin G (IgG) antibodies against pertussis in serum samples. Results were compared among 11 age groups. Univariate and multivariate analysis were used to analyze the associations among the rates of pertussis IgG seropositivity and the geometric mean concentration (GMC) levels of pertussis IgG and the related factors.Results: A total of 3360 subjects with available information were included, with 1745 male and 1615 female. Of these, 59.6% subjects had a clear immunization history of diphtheria–tetanus–pertussis vaccine (DTP). The vaccination rates of DTP had a declined trend with older age. The rate of pertussis IgG seropositivity was 69.9% (95% confidence interval: 68.3–71.5) and the GMC for pertussis IgG was 48.46 U/ml. Significantly higher seropositivity and GMC for pertussis IgG were found in subjects that had inoculation vaccine history or unknown history when compared those without inoculation of vaccine, lower in age groups <10, 20–29, and 30–39 y when compared to the other age groups evaluated.Conclusions: There are different distribution profiles both of the seropositivity and GMC for pertussis IgG for different age groups and immunization history of vaccine groups. In order to prevent pertussis occurrence, it is important to employ a booster dose of pertussis vaccine in adolescents and adults.

Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease

There are limited data on antibody response to vaccination in patients with inflammatory bowel disease (IBD). In this study, we aimed to assess the immunogenicity of a booster dose of pertussis vaccine in pediatric patients with IBD and to compare their response with healthy controls. We performed a multicenter, prospective, and controlled trial. Eligible for inclusion were children and adolescents (11-18 year olds), with no history of pertussis booster immunization after the age of 6 years or history of pertussis. Study population was divided into 4 groups: patients with IBD receiving no immunosuppressive therapy (group 1), those on thiopurines only (group 2), those on thiopurines and TNF-α agents (group 3), and healthy controls (group 4). Patients and controls received 1 dose of pertussis vaccine intramuscularly and were asked to record adverse effects for 3 days after vaccination. The primary outcome measure was adequate vaccine response, defined as the concentration of anti-Bordetella pertussis antibodies >11 μg/mL, measured between 4 and 8 weeks after the vaccination. In total, 138 subjects (111 patients and 27 controls) were enrolled in the study. Rates of adequate vaccine response did not differ among the 4 study groups (P = 0.11). Moreover, those patients with IBD who were on immunosuppressive therapy did not differ from those who were not (90.6% versus 88.2%, P = 0.37). No serious adverse effects in relation to the administration of vaccine were noted. Booster dose of pertussis vaccine was immunogenic and safe in pediatric patients with IBD.

The seroepidemiology of Immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study

BackgroundPertussis is a reported vaccine-preventable respiratory disease in China. Because the routine laboratory methods for diagnosis are not in use, the reported cases are mainly in infants with classical paroxysmal cough and the true incidence related to pertussis is most likely under estimated. In China, however, few studies have attempted to address this issue. The purpose of this cross sectional study was to estimate the incidence rates using the method of sero-epidemiology of immunoglobulin (Ig) G antibodies against pertussis toxin (PT) among healthy populations in China.MethodsBlood samples were obtained from 1313 healthy individuals aged 0 to 95 years in Guangdong province of China throughout September 2010. Serum IgG antibodies against PT were determined by commercial ELISA kits. Subjects with concentration of anti-PT IgG higher than 30 IU/mL were indicated to have recent Bordetella pertussis infection, if they have not received a booster dose of pertussis vaccine within one year.ResultsOf the 1313 study subjects, 117 (8.91%) were found to have anti-PT antibodies higher than 30 IU/mL. The estimated incidence of recent infection was thus 9395 per 100,000 for individuals older than 7 years. Peaks of the estimated incidence rate of recent infection were found to be 11561 per 100,000 in age group of 41–50 years and 11428 per 100,000 in the group aged 13–19 years.ConclusionsOur study indicated that B.pertussis infections are considerablely common, particularly in adolescents and adults in China. The study also stresses the importance of laboratory diagnosis for pertussis and employment of booster dose of pertussis vaccine in adolescents and adults in this country.

Recent findings on pertussis epidemiology in Turkey

The World Health Organization (WHO) reports that pertussis remains one of the least well-controlled vaccine-preventable diseases. It is supposed that the incidence of reported pertussis among adolescents, adults, and young infants has increased over the past decade. The aim of this study is to evaluate recent epidemiological data on pertussis in Turkey by regions. Data on vaccination coverage and pertussis incidence between 1986 and 2005 obtained from the Expanded Programme on Immunization national surveillance database of the Ministry of Health of Turkey were analyzed. Age and geographical distribution of the reported cases between 2000 and 2005 were evaluated. It was found that third-dose vaccination coverage increased from 1986 (45%) to 2005 (90%). In 2005, pertussis incidence tended to decrease (0.38 per 100,000) compared to 1986 (2.03 per 100,000). Even though only up to 6.5% of the cases were > or =15 years of age until 2005, 16.9% of them were included in this age group in 2005. It was observed that vaccination coverage rates steadily increased and pertussis incidence decreased by years despite some regional differences. In Turkey, pertussis incidence appears to be reaching the WHO targets, except East Anatolia. It is possible that waning immunity is responsible for the change of the age distribution of pertussis cases. However, priority should be given to strengthening available vaccination efforts throughout the country. A booster dose of pertussis vaccine in adolescence might be required in the future.

Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage.

Although France has had a vaccination program for 40 years, since 1990, an increase in whooping cough cases with parent-infant transmission has been observed. This study prospectively assessed the frequency of Bordetella pertussis infection in adults who consulted general practitioners for a persistent cough without an evident diagnosis. Among 217 patients, 70 (32%) confirmed whooping cough cases were identified. One case was culture positive, 36 were polymerase chain reaction positive, and 40 had increases or decreases of > or =2-fold in anti-pertussis toxin IgG titer between serum samples collected during the acute and convalescent phases. The median duration of cough in confirmed cases was 49 days (range, 13-123 days). Of the patients, 60% reported vaccination, and 33% reported whooping cough in infancy. Pertussis should be considered for diagnosis of acute and chronic cough in adults. Future studies should evaluate the public health interest of booster doses of pertussis vaccine in adults.